-

Monsanto Wins Third Circuit Court of Appeals Ruling in Schaffner v. Monsanto

Decision presents pathway to take preemption argument to U.S. Supreme Court

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, the Third Circuit Court of Appeals issued its ruling in Monsanto’s favor in the Schaffner v. Monsanto case, unanimously finding that the state-based failure-to-warn claims in this case are expressly preempted by the FIFRA statute.

This decision creates a circuit split with prior decisions of the Ninth and Eleventh Circuits on the central legal issues in the Roundup litigation and underscores the need for consistency on this important topic from a federal standpoint.

In response to the Schaffner v. Monsanto ruling, Monsanto issued the following statement:

“The Company is pleased with the unanimous decision from the Third Circuit holding that plaintiff’s state-based warning claims are expressly preempted by FIFRA. The Court concluded that ‘the alleged state-law duty to include the Cancer Warning on Roundup’s label imposes requirements that are different from those imposed under FIFRA, and that it is therefore preempted by FIFRA.”

“This decision on federal preemption, a cross-cutting issue in this litigation, creates a circuit split among the federal appellate courts and necessitates a review by the U.S. Supreme Court to settle this important issue of law. The Company is considering the impact of this ruling on other pending litigation and looks forward to presenting its arguments, as fully embraced by the Third Circuit, to the U.S. Supreme Court.”

“Bayer continues to stand fully behind its Roundup™ products – critical tools that farmers rely on to produce affordable food and feed the world – as the weight of scientific evidence and the conclusions of expert regulators worldwide continue to support the safety of glyphosate-based herbicides and that they are not carcinogenic.”

Contacts

Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

Court Grants Final Approval to Roundup™ Class Settlement

ST. LOUIS--(BUSINESS WIRE)--Today, a Missouri state court granted final approval of the U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging non-Hodgkin's lymphoma (NHL) injuries through a long-term claims program. The Court’s final approval order is subject to appeal. The class settlement, combined with the U.S. Supreme Court’s favorable ruling in June in the Durnell case, are mutually reinforcing pillars in the company’s multipronged strategy design...

Bayer’s SUNHARBO® (asundexian) Now Available in the United States

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that SUNHARBO® (asundexian), 50 mg tablets, is now available to order in the United States. Hospitals, health systems and pharmacies have immediate access to order the product for inventory. SUNHARBO is the first approved Factor XIa inhibitor in the U.S. and represents the first in a new class of medicine.1 SUNHARBO is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic isc...

Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat...
Back to Newsroom